SCHEMBL26732995

SCHEMBL26732995

O=c1[nH]nc(OC(F)F)c2ccc(Br)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 3/20 0.43
▸ WDR77 Q9BQA1 3/20 0.43
▸ CHEK1 O14757 3/20 0.39
▸ JAK2 O60674 3/20 0.39
▸ PIM1 P11309 2/20 0.39
▸ FLT3 P36888 2/20 0.39
▸ DYRK1A Q13627 2/20 0.39
▸ AURKA O14965 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ PAK4 O96013 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ MET P08581 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ PDGFRA P16234 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29426590 1.00 PRMT5 (0.43) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL26732994 0.94 PRMT5 (0.40) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL6312760 0.81 PRMT5 (0.43) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL29426556 0.79 PRMT5 (0.46) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL26732891 0.79 PRMT5 (0.46) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL20945200 0.75 PRMT5 (0.43) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL26732571 0.74 PRMT5 (0.49) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL30984825 0.74 PRMT5 (0.49) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL26732624 0.74 PRMT5 (0.43) PRMT5WDR77CHEK1JAK2PIM1
SCHEMBL26732890 0.73 PRMT5 (0.43) PRMT5WDR77CHEK1JAK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 — — US disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 PRMT5 1868/4885WDR77 1384/4885CHEK1 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback